Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 14 (final count)
- Started
- Aug 31, 2022
- Main results expected
- Apr 17, 2025
- Fully finished
- Mar 11, 2027
- Results posted
- Jun 25, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs)
Measured over: Up to 28 days
DE Phase: Number of Participants With Adverse Events (AEs)
Measured over: Up to approximately 137 weeks
DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Measured over: Baseline (Day 1) and up to 137 weeks
DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Measured over: Baseline (Day 1) and up to 137 weeks
CE Phase: Overall Response Rate (ORR)
Measured over: Up to 137 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07150104 · record last updated 2026-06-25 · checked 2026-11-09 15:47 UTC